• Careers
  • Contact
Intensity Therapeutics
Intensity Therapeutics
  • Home
  • Company
    • Introduction
    • Senior Management Team
    • Board of Directors
    • Scientific Advisors
  • Clinical Research
    • Overview
    • FAQs
    • For Patients
  • Technology
    • DfuseRx℠ Product Discovery Technology
    • Pipeline
    • Lead Product: INT230-6
    • Mechanism of Action
    • Intellectual Property and Patents
  • Partnerships
  • News & Events
    • Press Releases
    • Events and Presentations
    • Intensity Therapeutics in the News
    • Publications, Papers and Posters
  • Investors
Intensity Therapeutics
  • Home
  • Company
    • Introduction
    • Senior Management Team
    • Board of Directors
    • Scientific Advisors
  • Clinical Research
    • Overview
    • FAQs
    • For Patients
  • Technology
    • DfuseRx℠ Product Discovery Technology
    • Pipeline
    • Lead Product: INT230-6
    • Mechanism of Action
    • Intellectual Property and Patents
  • Partnerships
  • News & Events
    • Press Releases
    • Events and Presentations
    • Intensity Therapeutics in the News
    • Publications, Papers and Posters
  • Investors
  • Careers
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • Events & Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Contacts
    • FAQ
  • Financials
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • Events & Presentations
  • Email Alerts
Mar 24, 2021 8:00am EDT

Intensity Therapeutics, The Ottawa Hospital and The Ontario Institute for Cancer Research Sign Agreements to Conduct a Phase 2 Randomized, Window of Opportunity Trial in Early-Stage Breast Cancer

Nov 11, 2020 8:02am EST

Intensity Therapeutics Reports Favorable Data of INT230-6 from the Ongoing Phase 1/2 Study (IT-01/KEYNOTE A10) in Patients with Advanced Solid Tumors at SITC 2020 (Abstract 411)

Sep 17, 2020 8:02am EDT

Intensity Therapeutics Doses First Patient with Combination of INT230-6 and Bristol Myers Squibb’s Yervoy® in a Phase 2 Study

Sep 09, 2020 8:02am EDT

Intensity Therapeutics Doses First Patients with Combination of INT230-6 and Merck’s Keytruda® in Phase 2 Studies

Jun 25, 2020 7:36am EDT

Intensity Therapeutics Announces Publication of Research Reporting that Intratumoral Administration of INT230-6 Demonstrates Tissue Dispersive Properties, Tumor Regression and Elicits Systemic Adaptive Immunity

May 20, 2020 7:35am EDT

Intensity Therapeutics’ Abstract (#3016) Selected for Oral Presentation as Part of a Poster Discussion Session at ASCO 2020

Apr 14, 2020 7:35am EDT

Intensity Therapeutics Signs Clinical Collaboration Agreement with Bristol Myers Squibb for Advanced Solid Tumors

Mar 30, 2020 7:35am EDT

Intensity Therapeutics Reports Safety Results from First Cohort of the KEYNOTE A10 Combination Clinical Trial of INT230-6 and Keytruda®

Jan 08, 2020 7:35am EST

Intensity Therapeutics to Participate in East/West CEO Conference

Nov 07, 2019 7:35am EST

Data From Intensity Therapeutics’ Phase 1/2 Study of INT230-6 Highlight Prolonged Disease Control, Abscopal Effects and Immune Response Activity in Patients With Advanced Solid Tumors

  • arrow_back
  • 1…
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
  • Privacy Policy
Menu
  • Privacy Policy

© 2025 Intensity Therapeutics. All rights reserved.

Linkedin Twitter